Clinical trialsCompany release

Summit starts Phase III HARMONi-10 of ivonescimab against durvalumab in Stage III NSCLC

🇺🇸 Summit Therapeutics Inc. (SMMT) · Wed 18 Nov 2026

The global, open-label study could support registration and tests the PD-1 x VEGF bispecific as consolidation after chemoradiation in unresectable disease, with progression-free survival as its primary endpoint.

Summit Therapeutics announced on 18 November 2026 that it has begun HARMONi-10, a global, open-label Phase III trial that it describes as potentially registration-enabling. The study will evaluate ivonescimab, a PD-1 x VEGF bispecific antibody, in locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC).

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Summit Therapeutics Inc. ↗

Article written by VigiEye from the official source (Summit Therapeutics Inc.). Claims are the company's own. AI-assisted; check the source before acting.